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N E U R O S C I E N C E
Noncanonical function of an autophagy protein 
prevents spontaneous Alzheimer’s disease
Bradlee L. Heckmann1*, Brett J. W. Teubner2, Emilio Boada-Romero1, Bart Tummers1, 
Clifford Guy1, Patrick Fitzgerald1, Ulrike Mayer3, Simon Carding4, Stanislav S. Zakharenko2, 
Thomas Wileman4,5, Douglas R. Green1*
Noncanonical functions of autophagy proteins have been implicated in neurodegenerative conditions, including 
Alzheimer’s disease (AD). The WD domain of the autophagy protein Atg16L is dispensable for canonical autophagy 
but required for its noncanonical functions. Two-year-old mice lacking this domain presented with robust -amyloid 
(A) pathology, tau hyperphosphorylation, reactive microgliosis, pervasive neurodegeneration, and severe be-
havioral and memory deficiencies, consistent with human disease. Mechanistically, we found this WD domain 
was required for the recycling of A receptors in primary microglia. Pharmacologic suppression of neuro-
inflammation reversed established memory impairment and markers of disease pathology in this novel AD 
model. Therefore, loss of the Atg16L WD domain drives spontaneous AD in mice, and inhibition of neuro-
inflammation is a potential therapeutic approach for treating neurodegeneration and memory loss. A decline in 
expression of ATG16L in the brains of human patients with AD suggests the possibility that a similar mechanism 
may contribute in human disease.
INTRODUCTION
Roles for autophagy in suppressing the pathogenesis of neurode-
generative conditions, including Alzheimer’s disease (AD) (1, 2) and 
a decline in expression of components of the autophagy machinery 
with age and in the AD brain (3–6), highlight the importance of this 
process in homeostasis. However, many autophagy proteins perform 
functions distinct from canonical autophagy (7, 8). For example, the 
WD domain of the autophagy protein Atg16L is required for the 
lipidation of the microtubule-associated protein 1A/1B light chain 3B 
(LC3) at single membranes, while it is dispensable for the Atg16L- 
mediated LC3 lipidation in canonical autophagy (9, 10). Autophagy 
and pathways that use the autophagy machinery are known to function 
in the regulation of amyloid generation, neuronal homeostasis, and 
-amyloid (A) clearance (11–14). It has been well established that A 
clearance occurs through vesicular trafficking processes character-
ized by single membranes, including endocytosis in microglial cells 
(14–19). A direct link between these processes and the lipidation of 
LC3 on these single membranes, events that require components of 
the autophagy machinery, has been demonstrated (9, 14, 20, 21).
RESULTS
Deletion of the Atg16L WD domain results in spontaneous 
AD pathology in mice
To determine the importance of the WD domain of Atg16L in cen-
tral nervous system physiology, we evaluated aged mice lacking the 
WD domain of Atg16L (Atg16LWD) (10). We observed that 2-year-old 
mice had robust deposition of endogenous murine A in the hippo-
campus (Fig. 1, A and B) and throughout the cerebral cortex com-
pared to littermate controls (fig. S1, A to C). Upon closer inspection, 
A pathology was characterized by a combination of extracellular 
aggregates and intraneuronal deposits (Fig. 1C). Most A was found 
to be soluble and consisting of both the A1–40 and A1–42 neurotoxic 
peptides (Fig. 1D). Although these findings are consistent with what 
is typically observed in human patients with AD (22), aged mice lack-
ing the WD domain of Atg16L did not present with dense-cored A 
plaques, characteristic of both human disease and those found in 
mouse models overexpressing mutant forms of human amyloid pre-
cursor protein (APP), as there was a lack of increased insoluble A 
(Fig. 1D). It is plausible that the lack of plaque formation is a result 
of inherent biochemical differences between endogenous mouse and 
human APP and the associated A-cleavage products. In particular, 
mouse A1–42 has a reduced propensity for forming -sheet struc-
tures compared to human A1–42, which may explain the absence of 
A plaques in WD domain–deficient mice where endogenous mouse 
A peptides are accumulating (23).
We also observed pervasive hyperphosphorylation of the 
microtubule-stabilizing protein Tau in the hippocampus (Fig. 2, 
A and B) with pronounced accumulation in the CA3 field (Fig. 2C) 
and throughout the brain as a whole (Fig. 2D and fig. S1D). The 
proline-directed kinase–dependent phosphorylation of Tau at serine 
residues 199 and 202 (S199/S202) is highly correlative to Tau phos-
phorylation observed in human AD (24). The S202 phosphorylation 
is a major contributing phosphorylation event in the development of 
human neurofibrillary tangles, defined as aggregates of hyperphospho-
rylated Tau and are a known disease-relevant epitope leading to 
synaptic and neuronal dysfunction (25–27). Consistent with obser-
vations in human AD brain (26, 28), Tau hyperphosphorylation was 
not restricted to a singular phosphorylation event. Phosphorylation of 
Tau at S404 and S416 was likewise substantially elevated in Atg16L 
WD domain–deficient mice (Fig. 2D). Moreover, the phosphoryla-
tion present in the Atg16LWD mice is on endogenous Tau, driven 
entirely by the sole genetic manipulation of the Atg16L WD domain. 
This Tau pathology is therefore fully independent of either ectopic 
or overexpression of human Tau or mutants of human Tau, models 
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frequently used to study these and other Tau phosphorylation events 
and associated physiological consequences.
Since aged Atg16LWD mice had robust A deposition and Tau 
hyperphosphorylation, we asked how the loss of the WD domain 
was contributing to endogenous A accumulation. It has been shown 
that components of the autophagy machinery are required for the 
recycling of A receptors in a process known as LC3-associated en-
docytosis (LANDO) (14), and defects in this recycling can lead to 
Fig. 1. Aged mice lacking the WD domain of Atg16L have robust A deposition. All mice analyzed at 2 years of age, unless otherwise noted. (A) Representative im-
munofluorescence imaging of hippocampal A. (B) Quantification of A mean fluorescent intensity (MFI) in the hippocampus; each point represents an individual mouse. 
(C) High-resolution representative imaging of both extracellular and intraneuronal A deposits in hippocampus. (D) Immunoblot analysis of whole-brain lysates for 
soluble and insoluble A, C99 fragment using the MOAB-2 antibody and specific analysis of A neurotoxic peptides 1 to 40 and 1 to 42. DAPI, 4′,6-diamidino- 2-phenylindole. 
****P < 0.0001.
Fig. 2. Aged mice lacking the WD domain of Atg16L have robust Tau hyperphosphorylation. (A) Representative imaging of S199/202 Tau phosphorylation in hip-
pocampus. (B) Quantification of Tau phosphorylation in the hippocampus; each point represents and individual mouse. (C) CA3 field–specific imaging of S199/202 Tau 
phosphorylation. (D) Immunoblot analysis of whole brain for multiple species of phospho-Tau (pTau) compared to total-Tau. Actin was used as a loading control. 
***P < 0.001.
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accumulation of A in the transgenic 5xFAD model (5, 14). There-
fore, to interrogate a plausible mechanism leading to A deposition, 
we evaluated LANDO-dependent recycling of the A receptors 
TREM2 (Triggering Receptor Expressed On Myeloid Cells 2), CD36, and 
Toll-like receptor 4 (TLR4) (29, 30) and the contribution of the WD 
domain of Atg16L to this process. We found that recycling of all three 
receptors was contingent on the WD domain of Atg16L in primary 
microglia, consistent with a putative role for this domain in the LANDO 
pathway (Fig. 3, A and B). This impairment in LANDO-dependent recycling 
led to the decreased secondary uptake of A in primary microglia 
lacking the WD domain of Atg16L (Fig. 3C). Therefore, failed A 
clearance through loss of LANDO may contribute to the observed 
accumulation in vivo, as suggested previously (14). It is important 
to note, however, that the WD domain of Atg16L has roles in other 
pathways marked by LC3- lipidation at single membranes, including 
xenophagy and LC3- associated phagocytosis (9, 10, 31). There-
fore, the abrogation of LANDO by deletion of the Atg16L WD 
domain may not be exclusively responsible for the A deposition 
observed in the aged Atg16LWD animals. However, it was evident that 
the effects observed are likely independent of canonical autophagy, 
as deletion of the WD domain of Atg16L had no effect on the auto-
phagy markers P62 (Sequestosome-1) and LC3-II in either whole 
brain or in ex vivo brain cultures treated with an inhibitor of lyso-
somal acidification (fig. S2, A and B). Together, these data suggest 
that full-length Atg16L is required for the LANDO- dependent re-
cycling of A receptors in microglia, and loss of the WD domain of 
Atg16L is sufficient to drive AD pathology of endogenous murine 
A and Tau in a process independent of canonical autophagy.
Mice lacking the WD domain of Atg16L display robust 
neuroinflammation
A consequence of A deposition in human disease and murine 
models of AD is the proinflammatory activation of microglia (32). 
We observed exacerbated activation of microglia in the hippocampi 
of mice lacking the WD domain of Atg16L compared to wild-type 
littermates at 2 years of age (Fig. 4, A and B). As observed with A 
and phospho-Tau, microglial activation was not restricted to the hip-
pocampus and was prevalent throughout the cortex (Fig. 4, C and D). 
In addition to up-regulation of Iba1 (Ionized calcium binding adaptor 
molecule 1), microglia in aged Atg16LWD mice displayed a transi-
tion from ramified to ameboid morphology (Fig. 4E), consistent with 
inflammatory polarization (33). The proinflammatory cytokines in-
terleukin-1 (IL-1), IL-6, and tumor necrosis factor– (TNF) are 
often elevated in brains of patients with AD and are known to be major 
components in disease progression (34). Consistent with this, we 
found that the aged Atg16LWD had increased neuroinflammation, as 
determined by measuring the expression of IL-1, IL-6, and TNF in 
the hippocampus when compared to littermate controls, again paral-
leling healthy versus AD pathology in humans (Fig. 4F).
Atg16L WD domain deficiency leads to neurodegeneration 
in aged mice
Since we observed endogenous A deposition, Tau phosphorylation, 
and neuroinflammation, all of which are risk factors for impaired 
neuronal function, we profiled the neuronal architecture and func-
tion in Atg16L WD domain–deficient mice. Compared to control 
littermates, 2-year-old Atg16LWD mice had widespread cleavage of 
caspase 3, consistent with apoptotic death (Fig. 5, A to C). In agree-
ment with cleavage of caspase 3, 2-year-old Atg16LWD mice had an 
increase in terminal deoxynucleotidyl transferase–mediated deoxy-
uridine triphosphate nick end labeling–positive (TUNEL+) neurons 
compared to wild-type animals, indicative of apoptosis and sugges-
tive of active neurodegeneration (Fig. 5D). Moreover, 2-year-old 
Atg16LWD mice had a robust reduction in total neurons within the 
hippocampus, quantified using the neuronal nuclei marker NeuN (fig. 
S3A). These data suggest that aged mice lacking the WD domain of 
Atg16L have an increased susceptibility for neuronal death and 
A-associated neuroinflammation.
We next evaluated the physiological function of neurons within 
the hippocampus. We hypothesized that apoptotic processes would 
affect synaptic function. Basal synaptic transmission at excitatory 
synapses between hippocampal CA3 and CA1 pyramidal neurons 
(CA3-CA1 synapses) was not affected in 2-year-old mice lacking the 
WD domain of Atg16L when compared to control littermates (fig. S3B). 
However, 2-year-old Atg16LWD mice had a substantial reduction 
in long-term potentiation (LTP) at CA3-CA1 synapses (Fig. 5E). While 
the deposition of neurotoxic A peptides has been linked to impair-
ments in synaptic plasticity in humans (35, 36), recent evidence 
suggests that soluble, nonfibrillary, or plaque-bound A species are 
Fig. 3. Atg16L WD domain deletion leads to impaired recycling of A receptors 
and decreased A uptake. (A) Representative image of receptor recycling for 
TREM2, CD36, and TLR4 in primary microglia of the indicated genotypes. (B) Quan-
tification of receptor recycling depicted as fluorescent area/total cell number. n = 4 
performed in triplicate. (C) Secondary A uptake measured in primary microglial cells 
of the indicated genotype. n = 3 performed in triplicate. **P < 0.01 and ***P < 0.001.
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more detrimental to synaptic function, as measured by impaired 
LTP and characterized by increases in neuroinflammation (37–39). 
Our findings herein regarding A deposition in nonplaque-like struc-
tures and the effects observed on LTP in the aged mice are notably 
similar to what has been shown in human AD brain samples (40).
As a consequence of reduced LTP, Atg16LWD mice presented 
with severe behavioral and memory deficiencies. Performances in 
the sucrose preference test (SPT), spontaneous alternation (Y-maze), 
and novel object recognition (NOR) were all drastically impaired in 
2-year-old mice lacking the WD domain of Atg16L compared to 
littermate controls (Fig. 5, F to I). No measurable differences in fluid 
intake or total number of arm entries for Atg16LWD mice compared 
to wild-type for the SPT and Y-maze, respectively, were observed 
(fig. S3, C and D). Atg16LWD mice displayed a trend toward in-
creased total exploration time during the NOR (fig. S3E). Although 
this effect was not significant, it is consistent with previous reports 
in both mice and humans with AD, where the exploration time is 
typically increased to offset the inability to discern either the object 
(mice) or the locale (human).
The aged Atg16L WD domain–deficient mice were produced on 
a mixed (C57BL6/J,129) background and were not fully inbred (10). 
Therefore, we performed a single-nucleotide polymorphism (SNP) 
background analysis and compared percentage of background strain 
to disease markers, including spontaneous alternation (behavioral) 
and A burden (pathological). No discernable influence of the pre-
vailing background strain was observed for either marker of disease 
(fig. S4A). As a whole, these data demonstrate that the loss of the WD 
domain of Atg16L and the associated upstream pathology leads to 
neuroinflammation, neurodegeneration, dysfunction in synaptic 
plasticity, and severe behavioral impairment consistent with highly 
progressive disease.
Inhibition of neuroinflammation alleviates AD pathology 
in Atg16LWD mice
Our results indicated that deletion of the WD domain of Atg16L 
leads to the age-associated development of an endogenous, sponta-
neous AD pathology in mice. We next asked whether the observed 
pathology and memory impairment could be reversed once established 
and to what extent of the behavioral pathology was a consequence 
of neurodegeneration compared to neuroinflammation. Inflam-
masome inhibition has been proposed as a putative therapeutic ap-
proach that reduces neuroinflammation and Tau phosphorylation 
(41–45). Therefore, we treated Atg16L WD domain–deficient mice 
with established disease (starting at 20 months of age) and behavioral 
impairment, as measured by both impaired spontaneous alternation 
and NOR (fig. S5, A and B) with the brain-penetrant inflammasome 
Fig. 4. Atg16L WD domain deletion results in reactive microgliosis and neuroinflammation. All mice were analyzed at 2 years of age, unless otherwise noted. 
(A) Representative immunofluorescence imaging of hippocampal microglial activation, as measured by Iba1. (B) Quantification of Iba1 MFI in the hippocampus; each 
point represents an individual mouse. (C) Representative imaging of microglial activation by Iba1 in the cerebral cortex. (D) Quantification of Iba1 MFI in the cerebral 
cortex; each point represents an individual mouse. (E) Morphological analysis of microglia marked by Iba1. (F) Quantitative PCR (qPCR) analysis of inflammatory cytokine 
expression from isolated hippocampi; n = 5 performed in triplicate. ***P < 0.001, **P < 0.01, and *P < 0.05.  o
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inhibitor MCC950 (46–50). Following 8 weeks of treatment, we ob-
served reduced levels of microglial activation in mice treated with 
MCC950 compared to control (Fig. 6A and fig. S6A). Moreover, 
there was a reduction in both cleaved IL-1b and cleaved caspase 1 in 
the brains of mice treated with MCC950, indicative of effective in-
flammasome inhibition (Fig. 6B). However, no differences in A depo-
sition between control and treated animals were observed (fig. S6B). 
Inhibition of neuroinflammation resulted in a marked reduction in 
both Tau phosphorylation (Fig. 6C and fig. S6C) and neurodegen-
eration, as measured by TUNEL staining (Fig. 6D).
Consequently, mice treated with MCC950 had a restoration in 
their behavioral and memory capacity, approaching that of wild-
type littermates in both the Y-maze (Fig. 6E) and NOR (Fig. 6F) 
assays, with control-treated mice continuing to exhibit behavioral 
decline when compared to treatment onset (fig. S5, A and B). No 
differences in arm entries or the exploration time were observed 
Fig. 5. Mice lacking the WD domain of Atg16L have active neurodegeneration, impaired synaptic plasticity, and memory impairment. All mice were analyzed at 
2 years, of age unless otherwise noted. (A) Representative immunofluorescence imaging of neuronal cleaved caspase 3 staining. (B) High-resolution imaging of hippo-
campal cleaved caspase 3 staining of neurons. (C) Quantification of cleaved caspase 3 MFIs in the hippocampus; each point represents an individual mouse. (D) Represen-
tative immunofluorescence of hippocampal TUNEL staining. (E) Hippocampal LTP is reduced in Atg16L WD domain–deficient mice. Normalized CA3-CA1 field excitatory 
postsynaptic potentials (fEPSPs) as a function of time before and after induction of LTP. (F) Sucrose preference as measured as a percentage compared to standard water. 
(G) Spontaneous alternation percentage, as measured by Y-maze analysis. Novel object (H) preference and (I) discrimination index, as measured by NOR analysis. 
***P < 0.001 and ****P < 0.0001.
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between the control and treated groups (fig. S6, D and E). Together, 
these results suggest that neuroinflammation is upstream of Tau 
phosphorylation and progressive neurodegeneration in AD pathol-
ogy and contributes to behavioral deficits beyond those caused by 
neuronal loss.
Regulators of LANDO, including Atg16L, are down-regulated 
in human AD
Since we observed a strong AD phenotype resulting from the abro-
gation of Atg16L function and robust neuroinflammation in mice 
deficient in the WD domain of Atg16L, we asked whether there were 
correlations between Atg16L and disease in human brain. Mixed 
sex and age cohorts of normal (healthy) versus AD human brain 
samples were analyzed (Fig. 7A). All AD samples were established as 
diseased before analysis and were confirmed for A burden (Fig. 7B). 
We first evaluated the expression of transcription factors involved 
in the regulation of genes associated with both canonical and non-
canonical autophagic functions (51, 52). We observed marked de-
creases in master regulators, including transcription factor EB (TFEB) 
and Eukaryotic Translation Initiation Factor 5A (EIF5), and de-
creased transcription of components of the machinery that regulates 
LANDO, including Rubicon (Fig. 7C). Furthermore, we observed like-
wise decreases in the protein expression of Atg16L, Rubicon, and Atg5 
and, to a lesser extent, FAK family kinase-interacting protein of 200 kDa 
(FIP200) in the diseased patient samples compared to non-AD, normal 
samples (Fig. 7, D and E). These results are consistent with previous find-
ings regarding decreased expression of autophagy genes with age and 
further in AD (53–55); however, we directly found decreases in two 
key regulators of LANDO (Atg16L and Rubicon), which have, to date, 
not been described. Although these data are not sufficient to directly 
link defects in the LANDO machinery with AD establishment in humans, 
they do illustrate a relationship between the expression of the LANDO 
machinery and AD that is correlative to disease pathology in the spon-
taneous age-associated AD observed in the Atg16L WD-deficient mouse.
Fig. 6. Therapeutic response following inhibition of neuroinflammation in Atg16L WD-deficient mice with established AD pathology. Mice were treated as con-
trol or with MCC950 for 8 weeks. (A) Representative imaging of microglial activation by the Iba1 expression in the hippocampus. (B) Immunoblot analysis of in-
flammasome inhibition following MCC950 treatment. (C) Representative imaging of S199/202 Tau phosphorylation in CA3 field of the hippocampus. (D) Representative 
imaging of hippocampal cell death by TUNEL. (E) Spontaneous alternation percentage, as measured by Y-maze analysis. (F) Novel object preference and discrimination 
index, as measured by NOR analysis. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. n.s., not significant.
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DISCUSSION
Previously, we demonstrated that ablation of components of LANDO 
in microglia markedly exacerbate AD pathology in a transgenic mu-
rine model (5xFAD) (20). Our findings reported herein indicate that 
deletion of a single domain of the autophagy protein Atg16L, required 
for LANDO, is sufficient for driving spontaneous, age-associated AD 
pathology in mice. This represents a novel endogenous establishment 
of AD in mice that recapitulates the primary markers of human dis-
ease in the absence of overexpression of human disease drivers in-
cluding mutant forms of APP, presenilin 1, or Tau. Although we do 
not have direct evidence linking deficiencies in LANDO or other 
noncanonical functions of the autophagy machinery to AD in hu-
mans, we observed a down-regulation in the expression of compo-
nents of the LANDO machinery in human patients with AD. It is 
tempting to speculate that chronic or sustained suppressions in the 
expression of this machinery, as suggested previously (14) and con-
sequential impairment in LANDO, are contributing factors to the 
establishment and progression of AD in humans, likely through in-
creased neuroinflammatory processes.
We observed that deficiency in the WD domain of Atg16L led to 
A deposition that was highly characterized by soluble A peptides 
1 to 40 and 1 to 42, both of which are highly neurotoxic and neuro-
inflammatory (56–58) and have been theorized as primary drivers 
of AD, more so than fibrillary or plaque-associated A (59, 60). 
Central to this idea is the induction of neuroinflammation by soluble 
A peptides (14, 61), which is observed in the WD domain–deficient 
mice. We further found that established disease in this model can be 
reversed through inhibition of neuroinflammation. Decreased neuro-
inflammation led to reduced Tau phosphorylation and reductions in 
active neuronal cell death, leading to improved cognitive function, 
suggesting that sustained neuroinflammation directly affects the 
ability of neurons to signal, in addition to functioning as a primary 
driver of neuronal death. Some previous studies evaluating the effi-
cacy of targeting neuroinflammation in AD have observed decreases 
in A burden following inflammasome inhibition (42, 44, 47). How-
ever, we failed to see any reduction in A deposition following 
MCC950 treatment. The sustained A deposition we observe is like-
ly a result of the inability to efficiently clear A as a consequence of 
impaired LANDO at the genetic level, which we have reported pre-
viously (14).
It is clear that exacerbated and sustained neuroinflammation is a 
key component in the establishment and progression of AD and 
that noncanonical functions of the autophagy machinery in path-
ways such as LANDO, which are correlative to AD in humans, are 
Fig. 7. Down-regulation of LANDO machinery in human AD. (A) Identification and information on normal and patients with AD–derived samples used. (B) Representative 
immunofluorescence imaging showing A deposition in normal versus AD samples to confirm disease state. (C) qPCR analysis of transcriptional regulators and compo-
nents of the LANDO machinery from whole-brain RNA. (D) Immunoblot analysis of components comprising the LANDO or autophagy machinery in whole-brain lysates. 
(E) Quantification of protein expression. *P < 0.05 and **P < 0.01. Rbcn, Rubicon; A.U., arbritrary units.
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critical regulators of inflammatory activation in response to A. The 
mechanism by which LANDO is able to link A recognition with 
inflammatory regulation remains elusive; however, it is plausible that 
the reduced recycling of A receptors leads to sustained intracellu-
lar signaling following receptor activation. Likewise, it is plausible 
that a direct interaction between the LC3+ endosome containing A 
and downstream inflammatory complexes such as the NOD-, LRR- 
and pyrin domain-containing protein 3 (NLRP3) inflammasome exists; 
however, currently, this is speculative.
Cumulatively, we found that singular alterations in components 
of the LANDO pathway are sufficient to drive pervasive, spontaneous 
AD. Furthermore, we suggest that neuroinflammation is centric to 
AD establishment and progression upstream of neurodegeneration 
and can be suppressed by LANDO. Last, we show that targeting neuro-
inflammation is a viable therapeutic approach to prevent neuro-
degeneration and restore cognitive function.
MATERIALS AND METHODS
Reagents, antibodies, and qPCR oligos
The following primary antibodies were used for immunofluorescence 
staining, immunoblot, and/or receptor recycling assays: anti-A 
MOAB-2 (Novus Biologicals, NBP2-13075), anti-A1–42 specific (EMD 
Millipore, AB5078P), anti-A1–40 specific (AbBiotec, 251360), 
anti-S199/202 Tau (Thermo Fisher Scientific, 44-768G), anti-S404 Tau 
(Cell Signaling Technology , 35834), anti-S416 Tau (Cell Signaling, 
15013), anti-Tau (Cell Signaling, 46687), anti-Iba1 (Novus, NB100-
1028), anti-NeuN (Abcam, ab177487), anti–cleaved caspase 3 (Cell 
Signaling, 9664), anti–-actin horseradish peroxidase (HRP; Thermo, 
MA1-91399), anti-LC3 (Cell Signaling, 2775), anti-p62 (Sigma, 
P0067), anti-TREM2 (R&D Systems, MAB17291), anti- CD36 
(Abcam, ab23680), anti-TLR4 (Abcam, ab22048), anti–IL-1 (Cell 
Signaling, 12703), anti–cleaved IL-1 (Cell Signaling, 83186), anti–
caspase 1 (Cell Signaling, 3866), anti–cleaved caspase 1 (Cell Sig-
naling, 4199), anti-Rubicon (Cell Signaling, 8465), anti-FIP200 
(Cell Signaling, 12436), and anti-Atg5 (Cell Signaling, 12994). TUNEL 
staining was achieved using the Click-iT TUNEL Alexa Fluor 488 (AF488) 
Imaging Assay kit (Invitrogen) according to the manufacturer’s in-
structions on brain sections prepared and imaged, as described be-
low. A1–42 labeled with either AF488 or TAMRA was purchased 
from AnaSpec and prepared for the A uptake assay, as described 
previously (14).
The following oligos (IDT; Integrated DNA Technologies) were used 
for reverse transcription polymerase chain reaction (RT-PCR; represented 
as 5′-3′ for each primer): actin, ATGGAGGGGAATACAGCCC 
(forward) and TTC TTTGCAGCTCCTTCGTT (reverse); Iba1, 
CAGACTGCCAGCCTAAGACA (forward) and AGGAATT 
GCTTGTTGATCCC (reverse); TNF, CCTGTAGCCCACGTC-
GTAGC and AGCAATGACTCCAAAGTAGACC (reverse); IL-1, 
CACAGCAGCACATCAACAAG (forward) and GTGCTCAT-
GTCCTCATCCTG (reverse); IL-6, GAGGATACCACTCCCAA-
CAGACC (forward) and AAGTGCATCATCGTTGTTCATACA 
(reverse); TFEB, CCTGGAGATGACCAACAAGCAG (forward) 
and TAGGCAGCTCCTGCTTCACCAC (reverse); EIF5, GAG-
CAGAAGTACGACTGTGGAG (forward) and CAGGTTCA-
GAGGATCACTGCTG (reverse); TFE3, GATCATCAGCCTG-
GAGTCCAGT (forward) and AGCAGATTCCCTGACACAGGCA 
(reverse); Atg16L1, CTACGGAAGAGAACCAGGAGCT (for-
ward) and CTGGTAGAGGTTCCTTTGCTGC (reverse); and 
Rubicon, CCTGCTCGGGGATAGACAGTA (forward) and CT-
GGCAAACATGGACGCATC (reverse).
Mice
Deletion of the WD domain of Atg16L (Atg16LWD) was achieved, 
as previously described (10). In brief, two stop codons were imme-
diately inserted into exon 6 of murine Atg16L1 after glutamate E230 
to preserve binding sites for WIPI2 (WD Repeat Domain, Phospho-
inositide Interacting 2) (required for canonical autophagy) but prevent 
translation of the linker and WD domain. Mice were produced and 
maintained on a mixed 129, C57BL/6 background.
Unless otherwise noted, all experiments were performed on 
mixed-sex cohorts at 2 years of age. Mice treated with MCC950 or 
vehicle control were mixed-sex cohorts, 20 months of age at time of 
treatment onset, and were treated for 8 weeks, as described below. 
Mice were produced and aged at the University of East Anglia in 
accordance with the U.K. Home Office guidelines and under the U.K. 
Animals (Scientific Procedures) Act 1986. All mice were housed in 
pathogen-free facilities, in a 12-hour light/dark cycle in ventilated 
cages, with chow and water supply ad libitum before, during, and 
following transfer from the University of East Anglia to St. Jude Chil-
dren’s Research Hospital. All mice were allowed to acclimate for a 
period of at least 6 weeks before analysis or experimental usage. The 
St. Jude Institutional Animal Care and Use Committee approved 
all procedures in accordance with the Guide for the Care and Use of 
Animals.
The genetic backgrounds of mice used were assessed at the 
DartMouse Speed Congenic Core Facility at the Geisel School of 
Medicine at Dartmouth. DartMouse uses the Illumina Inc. (San Diego, 
CA) Infinium genotyping assay to interrogate a custom panel of 
5307 SNPs spread throughout the genome. The raw SNP data were 
analyzed using DartMouse’s SNaP-Map and Map-Synth soft-
ware, allowing the determination for each mouse of the genetic 
background at each SNP location. Background strain percentage 
was subsequently compared against markers of disease patholo-
gy to evaluate any influence stemming from variations in back-
ground (see fig. S3A).
Human samples
Commercial protein and RNA lysates from whole brain of either 
normal or AD donors were purchased from Biochain and Novus 
Biologicals. Lysates used for immunoblot analysis were prepared ac-
cording to the manufacturer’s instructions. Total RNA lysates were 
processed for complementary DNA, as described below. Donor in-
formation was provided by the supplier and is included herein.
MCC950 inflammasome inhibition in vivo
Mice with established disease (described above) were treated for 
8 weeks with either a vehicle (control) or MCC950 (Invivogen), as 
reported previously (46). In brief, MCC950 was suspended in 100% 
dimethyl sulfoxide (DMSO) and titrated to a working dose using 
sterile water. The final concentration of DMSO in the injection was 
<1%. Matching solution without MCC950 was used as the vehicle 
(control). Mice were injected every 3 days for 8 weeks at a dose of 
10 mg/kg via intraperitoneal injection.
Primary microglial isolation and culture
Primary microglia were isolated from Atg16LWD or littermate 
Atg16L+/+ control animals, as described previously (50). Isolated cells 
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were subsequently cultured and maintained in complete Dulbecco’s 
modified Eagle’s medium (DMEM) [10% fetal bovine serum, 200 mM 
l-glutamine, and penicillin-streptomycin (100 U/ml)] at 37°C with 
5% CO2.
Microscopy and image analysis
Cells were cultured in four-well chamber slides (Ibidi) and were fixed 
and stained, as indicated. In brief, cells were fixed with 4% parafor-
maldehyde (PFA) for 10 min. Followed by permeabilization using 
0.1% Triton X-100 for 5 min. Cells were blocked in 0.5% bovine serum 
albumin (BSA) in phosphate-buffered saline (PBS) for 30 min before 
staining with primary antibodies overnight at 4°C. Cells were then washed 
three times in PBS and then stained with the indicated fluorescent sec-
ondary antibodies for 30 min. Cells were subsequently washed three 
times with PBS and postfixed in 1% PFA for 10 min before imaging. 
For all live-cell–based imaging, cells were immediately transferred 
to an environment-controlled, live-cell imaging chamber (Ibidi).
For preparation of brain tissue, see the “Preparation of brain sam-
ples” section below. Slides were subjected to antigen retrieval using 
1% sodium citrate boiling for 20 min, followed by three times PBS 
washing. Slides were blocked in 0.5% BSA in PBS. Antibody stain-
ing was carried out, as described above. Following final washing, slides 
were mounted using the ProLong Diamond Anti-Fade mounting 
medium with 4′,6-diamidino-2-phenylindole.
All imaging was performed on either an Eclipse Ti-E TIRF/N-
Storm/epifluorescence microscope (Nikon) or a Marianis spinning 
disk confocal microscope [Intelligent Imaging Innovations (3i)] 
equipped with an electron-multiplying charge-coupled device camera. 
Image analysis including all quantification was performed using ei-
ther Nikon NIS-Elements Advanced Research Imaging software or 
Slidebook 6 (3i).
Image analysis for relative A, Iba1, and phospho-tau staining 
was achieved by quantifying the mean fluorescent intensity (MFI) 
of either Iba1 or phospho-tau signal using NIS elements. Analysis 
and quantification of microglial morphology were achieved using 
Slidebook 6 software. Morphological state was determined by mea-
suring cell diameter following three-dimensional reconstruction and 
confirmed by manual counting/analysis of microglia shape per de-
fined field across multiple areas of each slide.
Preparation of brain samples
Mice were anesthetized with isoflurane and perfused with either 
ice-cold PBS containing heparin (1 U/ml). Right brain hemispheres 
were fixed in 4% PFA overnight at 4°C, rinsed in PBS, and incubated 
overnight at 4°C in 30% sucrose before freezing in a 2:1 mixture 
of 30% sucrose and optimal cutting temperature compound. Serial 
20-m coronal sections were cut on a cryo-sliding microtome. Cor-
tices and hippocampi of the left brain hemispheres were carefully 
dissected out and flash frozen for biochemical analysis or processed 
for RNA isolation.
Cell and tissue lysis and immunoblot
Cells and tissue were lysed in radioimmunoprecipitation assay (RIPA) 
buffer for 30 min on ice [50 mM tris (pH 7.5), 150 mM NaCl, 1% 
Triton X-100, 0.5% deoxycholate, 0.1% SDS, protease inhibitor tablet 
(Roche), 1 mM NaF, 1 mM Na3VO4, and 1 mM phenylmethylsul-
fonyl fluoride]. Samples were boiled and centrifuged. After cen-
trifugation, supernatants were analyzed by SDS–polyacrylamide gel 
electrophoresis. All blots were imaged using HRP-conjugated sec-
ondary antibodies and enhanced chemiluminesence using a LI-COR 
Odyssey Fx imaging system (LI-COR Biosciences). All immunoblot 
analyses were performed using LI-COR Image Studio software. Pri-
mary antibodies used for immunoblotting analysis are listed in the 
“Reagents, antibodies, and qPCR oligos” section above.
Autophagy analysis in primary brain slices
Brain slices were isolated and cultured, as described previously (51, 52). 
Slices were maintained in artificial cerebrospinal fluid (ACSF) and 
were supplemented with PBS vehicle or 25 nM bafilomycin A1 for 
3 hours. Following treatment, slices were washed three times with 
PBS and subsequently homogenized in RIPA buffer, as described above.
Real-time RT-PCR
Total RNA was isolated from cells or tissue using the RNeasy Kit 
(Qiagen) according to the manufacturer’s instructions. First-strand 
synthesis was performed using the Moloney murine leukemia virus 
reverse transcriptase (Invitrogen). Real-time PCR was performed 
using the SYBR Green PCR Master Mix (Applied Biosystems) in an 
Applied Biosystems 7900HT thermocycler using the SYBR Green 
Detection protocol, as outlined by the manufacturer using the fol-
lowing PCR conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles 
of 95°C for 15 s and 60°C for 1 min. mRNA was normalized to actin 
allowing for comparison of mRNA levels. Sequences for mouse target 
primers are detailed in the “Reagents, antibodies, and qPCR oligos” 
section above.
Receptor recycling
For receptor recycling, cells were plated on four-well Ibidi tissue 
culture–coated chamber slides and allowed to reach 50% confluence. 
Cells were then blocked for 15 min in the presence of 10% normal 
donkey serum at 37°C. Primary antibodies targeting the indicated 
receptor (see reagent list) were then added at a dilution of 1:100 in 
1% donkey serum in DMEM, and cells were incubated at 37°C for 
1 hour. Antibody-containing medium was aspirated, and cells were 
acid washed with a cold DMEM (pH 2.0). Cells were returned to 
10% donkey serum in DMEM for 1 hour. Alexa Fluor 568–labeled 
secondary antibodies were diluted 1:1000 in 1% donkey-serum in 
DMEM and added to cells for 1 hour at 37°C to label recycled recep-
tors. Cells were subsequently acid washed, as described above, and 
then fixed in 4% PFA in PBS for 15 min. Cell-permeable Hoechst 
dye was added to label nuclei.
Following the above protocol, fluorescent signal from recycled 
receptors is intracellular and readily determined by fluorescent mi-
croscopy, as described above. Quantification of recycling was achieved 
by calculating the sum of AF568-fluorescent area divided by the to-
tal number of cells. Nikon NIS-Elements Advanced Research soft-
ware was used for all image analyses and quantification. This method 
is well established and used as previously reported (5).
Amyloid uptake
Primary and secondary A uptake was assayed as follows. Primary 
microglia were treated with 1 M Alexa Fluor 488–labeled A1–42. 
MFI for AF488 was determined by flow cytometry after 12 hours 
and considered as the primary uptake. The TAMRA-labeled A1–42 
(1 M) was subsequently added to the medium following the pri-
mary uptake phase. MFI for TAMRA was assessed by flow cytometry 
12 hours following the primary uptake time point. This time point 
constitutes the secondary uptake.
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Electrophysiology
Acute transverse hippocampal slices (400 m) were prepared, as pre-
viously described (62). Briefly, mouse brains were quickly removed 
and placed in cold (4°C) dissecting ACSF containing 125 mM 
choline-Cl, 2.5 mM KCl, 0.4 mM CaCl2, 6 mM MgCl2, 1.25 mM 
NaH2PO4, 26 mM NaHCO3, and 20 mM glucose (285 to 295 mosm) 
under 95% O2 and 5% CO2. After dissection, slices were incubated 
for 1 hour in ACSF containing 125 mM NaCl, 2.5 mM KCl, 2 mM 
CaCl2, 2 mM MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, and 10 mM 
glucose (285 to 295 mosm) under 95% O2 and 5% CO2 at room 
temperature and then transferred into the submerged recording 
chamber and superfused (2 to 3 ml/min) with warm (30° to 32°C) 
ACSF. The field recordings were performed by using a setup with 
eight submerged recording chambers (Campden Instruments). The 
field excitatory postsynaptic potentials (fEPSPs) were recorded from 
the CA1 stratum radiatum by using an extracellular glass pipette (3 to 
5 megohms) filled with ACSF. Schaffer collateral/commissural fibers 
in the stratum radiatum were stimulated with a bipolar tungsten 
electrode placed 200 to 300 m away from the recording pipette.
Behavior and memory analysis
For SPTs, mice were individually house and allowed to acclimate to 
the testing room for 48 hours before starting the experiment. A dual- 
bottle setup was introduced where both bottles contained only stan-
dard water. Again, mice were allowed to acclimate to the dual-bottle 
setup for 3 days. After acclimation, one bottle was replaced with a 
2% sucrose solution. Water consumption was monitored daily for 
4 days. Bottles were rotated daily to minimize side bias and normal-
ized for leakage. All results are shown as the averaged consumption 
and preference over the 4-day test period.
For Y-maze spontaneous alternation analysis, mice were housed 
in the testing room and allowed to acclimate for 48 hours. The Y-maze 
test consisted of a single 5-min trial per mouse. Spontaneous alter-
nation (%) was defined as consecutive entries in three different arms 
(A, B, and C) divided by the number of possible alternations (total 
arm entries − 2). Mice with less than 5 arm entries during the 5-min 
trial were excluded from the analysis.
NOR was performed in an open-field box (40 cm by 40 cm). Mice 
were allowed to acclimate to the testing room for 48 hours. For ha-
bituation, mice were allowed to explore the open field for 15 min 
per day for 2 days. Mice were then exposed to two identical objects 
for 10 min on the day of testing. Two hours later, a novel object was 
introduced, and mice were allowed to explore for 5 min during the 
test phase. The time spent exploring each object was quantified man-
ually. Novel object preference (%) and the discrimination index [(time 
with novel)/(novel + familiar) × 100] were calculated for each mouse.
Statistical analysis
Data were plotted and analyzed with GraphPad Prism 7.0 software. 
Data are represented as mean ± SEM. Significance was calculated 
using Student’s t test, unless otherwise noted. All experiments were 
designed and are powered to a minimum of 0.8, as calculated using 
G*Power. Differences were considered statistically significant when 
the P value was less than 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/33/eabb9036/DC1
View/request a protocol for this paper from Bio-protocol.
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